VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Receives FDA Clearance to Commence Clinical Trials of VGX-1027, a Novel Oral Drug with Potent Anti-inflammatory Activity

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application for its lead anti-inflammatory compound, VGX-1027. VGX-1027 is an orally active, small molecule compound that has shown preclinical efficacy against various inflammatory diseases including Rheumatoid Arthritis (RA) and Type 1 diabetes (T1D).